Core Insights - The American Century U.S. Quality Growth ETF (QGRO) has made significant adjustments to its holdings, reflecting the flexibility of ETF managers in response to market movements [1][3][6] Fund Overview - QGRO was launched in September 2018 and charges 29 basis points for investing in U.S. firms with high growth potential and strong fundamentals [2] - The fund tracks the American Century U.S. Quality Growth Index, which screens for factors like income and quality using metrics such as cash flow and profitability [2] Recent Changes in Holdings - Notable changes in QGRO's portfolio include the dropping of at least two stocks and the addition of two new stocks, along with adjustments to the weights of six existing stocks [3] - Major tech companies such as Alphabet (GOOGL), Meta Platforms (META), and Amazon (AMZN) saw their weights decrease by 1.22%, 1.32%, and 1.74% respectively between November 21 and 24 [3] - Conversely, Amphenol Corporation (APH), Ralph Lauren Corporation (RL), and Expedia Group, Inc. (EXPE) experienced weight increases of 3.53%, 2.1%, and 1.33% respectively [4] Specific Stock Adjustments - The two stocks that were dropped from QGRO included Itron Inc. (ITRI) and Booz Allen Hamilton Holding Corporation (BAH), which had weights of 0.76% and 0.72% respectively before being removed [5] - The largest additions to the fund were Cardinal Health, Inc. (CAH) and HCA Healthcare, Inc. (HCA), with weights of 1.08% and 1.25% respectively [5] Performance Metrics - QGRO has achieved a year-to-date return of 12.4%, focusing on quality and growth-oriented companies [6] - The recent reduction in weight for three major tech stocks may attract investors looking to diversify into other rising companies [6]

Group 1: Upslope Capital Management Performance - Upslope Capital Management reported a strong performance in Q3 2025, achieving a net return of +8.8%, outperforming the S&P Midcap 400 ETF (+5.5%) and HFRX Equity Hedge Index (+3.8%) [1] Group 2: STERIS plc Overview - STERIS plc, headquartered in Dublin, Ireland, specializes in infection prevention products and services, with a market capitalization of $23.73 billion as of October 22, 2025 [2] - The stock of STERIS plc experienced a one-month return of -1.44% but gained 5.91% over the last 52 weeks, closing at $242.37 per share [2] Group 3: STERIS plc Investment Insights - STERIS plc is recognized as a leader in infection prevention and sterilization, with approximately 75% of sales derived from service and consumables, historically achieving high single-digit organic growth [3] - The company's valuation is considered reasonable at 22x 2026 EPS, and it maintains a strong balance sheet with 1x net leverage, presenting opportunities for capital deployment [3] - Long-term growth drivers for STERIS plc include an aging global population and ongoing innovations in healthcare procedures and technology [3] Group 4: Hedge Fund Interest in STERIS plc - STERIS plc was held by 50 hedge fund portfolios at the end of Q2 2025, an increase from 46 in the previous quarter, indicating growing interest among institutional investors [4]

Core Insights - Thermo Fisher Scientific Inc. reported third-quarter 2025 adjusted earnings per share (EPS) of $5.79, exceeding the Zacks Consensus Estimate by 5.27% and reflecting a year-over-year increase of 9.7% [1][8] - The company's revenues for the quarter rose 4.9% year over year to $11.12 billion, surpassing the Zacks Consensus Estimate by 1.99% [2][8] Revenue Breakdown - Life Sciences Solutions segment, accounting for 23.3% of total revenues, saw an 8.4% year-over-year increase to $2.59 billion, exceeding estimates [3] - Analytical Instruments segment, representing 17% of total revenues, reported a 4.7% year-over-year increase to $1.89 billion, slightly missing estimates [4] - Specialty Diagnostics segment, making up 10.6% of total revenues, increased 4% year over year to $1.17 billion, also missing estimates [5] - Laboratory Products and Biopharma Services segment, which constitutes 53.7% of total revenues, rose 4% year over year to $5.97 billion, surpassing estimates [6] Margin Performance - Gross margin for the quarter was 41.8%, an increase of 14 basis points year over year, despite a 4.7% rise in the cost of revenues [7] - Adjusted operating margin expanded to 22.6%, reflecting a 56 basis points increase [7][8] Financial Position - At the end of Q3 2025, the company had cash and cash equivalents and short-term investments totaling $3.55 billion, down from $6.39 billion at the end of Q2 [9] - Cumulative net cash from operating activities was $4.36 billion, compared to $5.38 billion a year ago [9] - The company has a strong dividend-paying history, with a five-year annualized dividend growth of 14.15% [9] Strategic Developments - The company announced a strategic collaboration with OpenAI to enhance the use of artificial intelligence across its operations, products, and services, aimed at accelerating scientific breakthroughs and improving productivity [11] - Recent product launches include the Olink Target 48 Neurodegeneration panel and the Thermo Scientific Talos 12 transmission electron microscope, contributing to growth [10][11]